Boston Scientific (BSX) Expected to Release Earnings on Wednesday

Boston Scientific (NYSE:BSX) is expected to release its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.83 per share and revenue of $5.3671 billion for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the business posted $0.75 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Boston Scientific Price Performance

Shares of BSX opened at $43.14 on Wednesday. The firm has a market capitalization of $64.12 billion, a price-to-earnings ratio of 18.05, a PEG ratio of 0.84 and a beta of 0.58. The firm’s fifty day simple moving average is $47.77 and its 200-day simple moving average is $64.93. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific declared that its board has initiated a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Insider Activity

In other news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently modified their holdings of the business. Sunbelt Securities Inc. lifted its holdings in shares of Boston Scientific by 33.0% in the 4th quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock valued at $135,000 after buying an additional 350 shares during the period. Compound Planning Inc. boosted its stake in shares of Boston Scientific by 14.7% in the fourth quarter. Compound Planning Inc. now owns 15,423 shares of the medical equipment provider’s stock valued at $1,471,000 after buying an additional 1,978 shares in the last quarter. Axxcess Wealth Management LLC grew its holdings in Boston Scientific by 130.9% during the fourth quarter. Axxcess Wealth Management LLC now owns 28,347 shares of the medical equipment provider’s stock worth $2,703,000 after acquiring an additional 16,068 shares during the period. Corient Private Wealth LLC grew its holdings in Boston Scientific by 11.1% during the fourth quarter. Corient Private Wealth LLC now owns 242,992 shares of the medical equipment provider’s stock worth $22,238,000 after acquiring an additional 24,194 shares during the period. Finally, Strive Financial Group LLC purchased a new position in Boston Scientific in the fourth quarter worth $1,499,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BSX. Leerink Partners decreased their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. Evercore set a $65.00 target price on shares of Boston Scientific in a research note on Monday, July 6th. Raymond James Financial restated an “outperform” rating and issued a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Stifel Nicolaus reduced their price objective on Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.84.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.